
Antibiotics
Latest News
Latest Videos

More News

Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.

Abdulwhab Shremo Msdi, PharmD, offers insights on its complexities, why institutions have been slower to include this dosing technique, and why clinicians need to consider this approach.

In a retrospective cohort study, a health system found this form of prophylaxis led to substantial reductions in 2 of 3 sexually transmitted infections (STIs) in a mostly male population.

New recommendations emphasize shorter, all-oral regimens for both drug-susceptible and drug-resistant TB.

Exploring the challenges and strategies for combating MDR Pseudomonas aeruginosa infections, as discussed with Jason Pogue, PharmD, BCPS, BCIDP

Jason M Pogue, PharmD, BCPS, BCIDP discusses the findings, pharmacokinetics, why ceftolozane-tazobactam may be the preferred choice for resistant infections, and more.

A small phase 2 study evaluated Debiopharm’s investigational antibiotic, afabicin, including its clinical response rate and safety profile of 2-3 weeks of treatment for staphylococcal bone and joint infections (BJI).

Amesh A. Adalja, MD, FIDSA outlined the importance of recognizing antibiotic resistance in healthcare settings, educating patients on responsible antibiotic use, and the need for new treatments and diagnostic tools.

Investigators propose limiting initial use of antibiotics for group A streptococcal pharyngitis in children after finding placebo noninferior in reducing symptoms.

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.

With AMR being a global priority, biosecurity-type policy around resistance may be part of the solution.

Jose Alexander, MD, offers some insights on the antimicrobial and its activity against various gram-negative pathogens such as pseudomonas, enterobacterales.

At ID Week 2024, in a late-breaking presentation, investigators are reporting it is safe to cut the antibiotic regimen in half without endangering patients for these infections.

A holistic, multifaceted approach with a variety of stakeholders are needed to address antimicrobial resistance (AMR). The recent UN meeting on this topic looked to bring together government leaders, industry, and public health officials to discuss strategies regarding the global health crisis.

The ideal parameter for vancomycin monitoring is the area under the curve, which can be calculated using pharmacokinetic equations or Bayesian software.

Part 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.

Jennifer Quinn, head of Global Value & Access, Debiopharm, offers insights on pull incentives and how they look to get more antibiotics to market.

This study revealed a significant decline in MSSA and a corresponding rise MRSA, particularly linked to COVID-19 social isolation measures.

A novel test is looking to ascertain this diagnostic information quickly to aid clinicians in making a determination of infections and more efficiently prescribe antimicrobials.

Continuous antibiotic infusions show positive results and may improve outcomes for patients with severe sepsis.

Initial studies show its effectiveness against various bacteria, including those resistant to standard treatments, and it is being developed in both intravenous and oral forms to improve patient access.

Long-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.

New predictive statistical modeling shows that antimicrobial resistance (AMR) deaths will rise steadily in the coming decades.

Kevin Nguyen, PharmD, offers some insights on some of the challenges in the outpatient setting with regards to stewardship, and novel strategies being utilized.

Mass distribution of azithromycin twice yearly to infants and children did not comply with WHO recommendation but reduced all-cause mortality.











































































































































































